Home › Compare › FIXX vs JEPQ

FIXX vs JEPQ: Dividend Comparison 2026

FIXX yields 213.97% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FIXX wins by $177.38M in total portfolio value
10 years
FIXX
FIXX
● Live price
213.97%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.43M
Annual income
$92,441,271.48
Full FIXX calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — FIXX vs JEPQ

📍 FIXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIXXJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIXX + JEPQ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
FIXX pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIXX
Annual income on $10K today (after 15% tax)
$18,187.65/yr
After 10yr DRIP, annual income (after tax)
$78,575,080.76/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, FIXX beats the other by $78,573,251.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIXX + JEPQ for your $10,000?

FIXX: 50%JEPQ: 50%
100% JEPQ50/50100% FIXX
Portfolio after 10yr
$88.74M
Annual income
$46,221,712.03/yr
Blended yield
52.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FIXX right now

FIXX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$2.70
+188.9% upside vs current
Range: $2.70 — $2.70
Altman Z
-2.8
Piotroski
4/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIXX buys
0
JEPQ buys
0
No recent congressional trades found for FIXX or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIXXJEPQ
Forward yield213.97% ✓11.10%
Annual dividend / share$2.00$6.16 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$177.43M ✓$44.8K
Annual income after 10y$92,441,271.48 ✓$2,152.59
Total dividends collected$167.81M ✓$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: FIXX vs JEPQ ($10,000, DRIP)

YearFIXX PortfolioFIXX Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$32,097$21,397.24$11,930$1,110.39+$20.2K → FIXX
2$98,530$64,186.20$14,133$1,224.34+$84.4K → FIXX
3$289,572$184,144.93$16,632$1,340.46+$272.9K → FIXX
4$815,624$505,782.06$19,454$1,457.97+$796.2K → FIXX
5$2,204,131$1,331,413.21$22,626$1,576.08+$2.18M → FIXX
6$5,721,029$3,362,608.71$26,175$1,694.09+$5.69M → FIXX
7$14,278,479$8,156,977.31$30,133$1,811.32+$14.25M → FIXX
8$34,304,224$19,026,251.97$34,531$1,927.17+$34.27M → FIXX
9$79,425,902$42,720,382.43$39,403$2,041.08+$79.39M → FIXX
10$177,426,987$92,441,271.48$44,787$2,152.59+$177.38M → FIXX

FIXX vs JEPQ: Complete Analysis 2026

FIXX — Stock

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Full FIXX Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this FIXX vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIXX vs SCHDFIXX vs JEPIFIXX vs OFIXX vs KOFIXX vs MAINFIXX vs XYLDFIXX vs QYLDFIXX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.